A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
A Phase 1, Uncontrolled, Open-label, Non-randomized, Dose-escalation Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors, Followed by an Uncontrolled, Non-randomized Study and an Uncontrolled, Randomized Study in Patients With Esophageal Squamous Cell Carcinoma or Head and Neck Squamous Cell Carcinoma
Kyowa Kirin Co., Ltd.
189 participants
Nov 1, 2023
INTERVENTIONAL
Conditions
Summary
This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). In Part 1b and Part 2, at least two dosing regimens and two dosing regimens by cancer type, respectively, will be selected, and the safety, tolerability, and efficacy of each regimen will be evaluated.
Eligibility
Inclusion Criteria18
- Patients who have given informed written consent.
- Male or female subjects ≥18 years of age, at time of signing informed consent.
- Subjects who are refractory to standard treatment, intolerant of standard treatment, for whom standard treatment does not exist, or who have refused standard treatment.
- Patients with measurable disease according to RECIST version 1.1
- Patients who have had the certaion periods between the date of completion of prior therapy and the date of enrollment
- Subjects who agree to have a tumor biopsy as part of the baseline examination. Patients who have difficulty in performing a tumour biopsy and have agreed to submit a previously collected stored specimen.
- Patients with an ECOG PS of 0 or 1 at baseline.
- Patients with haematopoietic, hepatic, renal, cardiac and respiratory functions that meet certain criteria in a baseline test.
- \) Patients with pathologically diagnosed advanced or metastatic solid tumors.
- Patients with pathologically diagnosed with advanced or metastatic esophageal cancer, or advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
- Patients with pathologically diagnosed squamous cell carcinoma.
- Patients who agree to undergo tumor biopsy after administration.
- Patients with pathologically diagnosed with advanced or metastatic esophageal cancer.
- Patients with pathologically diagnosed squamous cell carcinoma.
- Patients who agree to undergo tumor biopsy after administration.
- Patients with advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
- Patients with pathologically diagnosed squamous cell carcinoma.
- Patients who agree to undergo tumor biopsy after administration.
Exclusion Criteria9
- Patients with central or brain pia mater metastases that are untreated and symptomatic or that require treatment.
- Patients with concurrent multiple or synchronous cancers, or with iatrogenic multiple or synchronous cancers with a disease-free interval of 5 years or less.
- Patients receiving continuous systemic administration of steroids or other immunosuppressive drugs.
- Patients who have had a Grade 3 or higher allergic reaction to an antibody agent or an additive of the study drug.
- Patients who have not recovered to Grade 1 or below from adverse events caused by previously administered anticancer therapy.
- Patients with active interstitial lung disease or a history of active interstitial lung disease.
- Patients with infectious diseases requiring systemic treatment.
- Patients with a fever of 38.0°C or higher at the time of registration.
- Patients who test positive for Hepatitis B virus antigen or antibody, Hepatitis C virus antibody, or HIV antibody in a baseline test.
Interventions
KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06248411